Lei Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lei Yu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Zhenyu Jia
University of California, Riverside
73 shared publications - Kevyn Lopez Hart
Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, California. 1
72 shared publications - Lili Wang
Department of Systems Biology, Beckman Research Institute, City of Hope, Duarte, USA
72 shared publications - Mike Minh Fernandez
Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, California. 1
71 shared publications - Qiong Jia
Department of Botany & Plant Sciences, University of California, Riverside, CA 92527, USA
71 shared publications - Ren-Jang Lin
Irell & Manella Graduate School of Biological Sciences of the City of Hope, Duarte, CA, USA.
71 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Tumor-intrinsic IFNγ signaling and niche adaptation drive early colonization in ovarian cancer metastasis
The mechanisms enabling disseminating tumor cells to survive and colonize peritoneal niches during ovarian cancer metastasis remain incompletely understood. Here, we present MetTag, a single-cell barcoding and transcriptome profiling approach with time-stamped batch identifiers to resolve temporal dynamics of dissemination. Sequencing of MetTag barcodes reveals enrichment of early-disseminated clones across metastatic sites, and targeted depletion of pioneers diminishes the outgrowth of later arriving cells. MetTag-coupled single-cell RNA sequencing uncovers a distinct interferon-gamma-centric transcriptional trajectory enriched among pioneer clones. CRISPR/Cas9 screening and subsequent interferon-gamma receptor 1 knockout in pioneer cells significantly reduces metastatic burden, highlighting a critical window where active interferon-gamma signaling shapes the post-seeding metastatic niche and outgrowth. Mechanistically, the tumor-intrinsic interferon-gamma response and peritoneal macrophages cooperatively shield disseminating tumor cells from anoikis. Our study defines the temporal clonal architecture of peritoneal metastasis, revealing a first come, first served dissemination principle, where pioneer fitness determines the success of subsequent colonizers.
- 3 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTumor-intrinsic IFNγ signaling and niche adaptation drive early colonization in ovarian cancer metastasis
The mechanisms enabling disseminating tumor cells to survive and colonize peritoneal niches during ovarian cancer metastasis remain incompletely understood. Here, we present MetTag, a single-cell barcoding and transcriptome profiling approach with time-stamped batch identifiers to resolve temporal dynamics of dissemination. Sequencing of MetTag barcodes reveals enrichment of early-disseminated clones across metastatic sites, and targeted depletion of pioneers diminishes the outgrowth of later arriving cells. MetTag-coupled single-cell RNA sequencing uncovers a distinct interferon-gamma-centric transcriptional trajectory enriched among pioneer clones. CRISPR/Cas9 screening and subsequent interferon-gamma receptor 1 knockout in pioneer cells significantly reduces metastatic burden, highlighting a critical window where active interferon-gamma signaling shapes the post-seeding metastatic niche and outgrowth. Mechanistically, the tumor-intrinsic interferon-gamma response and peritoneal macrophages cooperatively shield disseminating tumor cells from anoikis. Our study defines the temporal clonal architecture of peritoneal metastasis, revealing a first come, first served dissemination principle, where pioneer fitness determines the success of subsequent colonizers.
- Open Access
- 24 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Integration of gene expression and alternative splicing enhances IGHV mutation status and survival risk prediction in chronic lymphocytic leukemia
The immunoglobulin heavy chain variable region (IGHV) mutation status is a key prognostic marker in chronic lymphocytic leukemia (CLL), shaping disease progression and therapeutic response. Current IGHV testing relies on molecular genomic analyses and requires specific laboratory tests, limiting its accessibility. Here, we developed an unbiased computational approach to accurately predict IGHV mutation status based on gene expression and alternative splicing profiles derived from transcriptome data. We showed that predicted IGHV status had a superior predictive power for overall and failure-free survival compared to conventional IGHV testing methods. Moreover, we identified significant novel associations between key transcriptomic features and genetic lesions, indicating potential but unexplored roles in CLL pathogenesis. Our results thus highlight a novel strategy for integrating molecular features to improve CLL prognosis, underscoring the prognostic value of RNA alternative splicing in CLL biology.
- 24 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIntegration of gene expression and alternative splicing enhances IGHV mutation status and survival risk prediction in chronic lymphocytic leukemia
The immunoglobulin heavy chain variable region (IGHV) mutation status is a key prognostic marker in chronic lymphocytic leukemia (CLL), shaping disease progression and therapeutic response. Current IGHV testing relies on molecular genomic analyses and requires specific laboratory tests, limiting its accessibility. Here, we developed an unbiased computational approach to accurately predict IGHV mutation status based on gene expression and alternative splicing profiles derived from transcriptome data. We showed that predicted IGHV status had a superior predictive power for overall and failure-free survival compared to conventional IGHV testing methods. Moreover, we identified significant novel associations between key transcriptomic features and genetic lesions, indicating potential but unexplored roles in CLL pathogenesis. Our results thus highlight a novel strategy for integrating molecular features to improve CLL prognosis, underscoring the prognostic value of RNA alternative splicing in CLL biology.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 10 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 10 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
FACS sorting and RhAMP SNP screening yield isogenic SF3B1 mutant clones
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
FACS sorting and RhAMP SNP screening yield isogenic SF3B1 mutant clones
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Cloning and mutagenesis primers
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Cloning and mutagenesis primers
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Splicing and growth phenotypes of HG-3 and MEC-1 SF3B1 mutant cell lines
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Splicing and growth phenotypes of HG-3 and MEC-1 SF3B1 mutant cell lines
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 3 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 3 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Aberrant 3’SS splicing profiles of SF3B1-mutated cell lines and primary CLL
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Aberrant 3’SS splicing profiles of SF3B1-mutated cell lines and primary CLL